Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | S100A4 | P26447 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28740590 | 0.98 | KMT2A (0.48) | KMT2AHTTALDH1A1CYP3A4DYRK1A | |
| SCHEMBL6830211 | 0.81 | XDH (0.50) | KMT2AHTTALDH1A1CYP3A4MAPT | |
| SCHEMBL30467812 | 0.80 | TDP1 (0.48) | KMT2AALDH1A1CYP3A4MAPTTDP1 | |
| SCHEMBL9367583 | 0.80 | TDP1 (0.48) | KMT2AALDH1A1CYP3A4MAPTTDP1 | |
| SCHEMBL202290 | 0.80 | ERN1 (0.41) | KMT2AHTTALDH1A1CYP3A4MAPT | |
| SCHEMBL29600703 | 0.80 | ERN1 (0.41) | KMT2AHTTALDH1A1CYP3A4MAPT | |
| SCHEMBL6512051 | 0.80 | ERN1 (0.41) | KMT2AHTTALDH1A1CYP3A4DYRK1A | |
| SCHEMBL5034039 | 0.80 | MAPT (0.46) | KMT2AHTTALDH1A1CYP3A4MAPT | |
| SCHEMBL26159111 | 0.79 | ALDH1A1 (0.39) | KMT2AHTTALDH1A1CYP3A4MAPT | |
| SCHEMBL203312 | 0.78 | INPPL1 (0.46) | KMT2AALDH1A1CYP3A4MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 491 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547713-B2 | O-pyridinequinone derivatives, the composition containing the derivatives, the process for preparation of the derivatives and the use of the derivatives | GU LIANQUAN | 2009-06-16 | — | — | US | claimed |
| CN-101343366-A | Nano-laminal compound with regular array of pyridine and its derivant, and preparation thereof | UNIV SHANGHAI (CN) | 2009-01-14 | — | — | CN | claimed |
| CN-1284773-C | Ortho-pyridinequinone derivative, composite containing said derivative, its preparation method and application | BAIRUI GLOBAL CO LTD (VG) | 2006-11-15 | — | — | CN | claimed |
| US-20060111405-A1 | O-pyridinequinone derivatives, the composition containing the derivatives, the process for preparation of the derivatives and the use of the derivatives | GU LIANQUAN | 2006-05-25 | — | — | US | claimed |
| EP-1569925-A1 | 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-09-07 | — | — | EP | claimed |
| WO-2004055003-A1 | 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| CN-1477099-A | O-pyridinoquinone derivative, composition containing the same, preparation method and use of the same | 百瑞全球有限公司 | 2004-02-25 | — | — | CN | claimed |
| CN-119053599-A | Bicyclic compounds | 安力高医药股份有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-12145925-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | ATLASMEDX, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| CN-114989164-B | Substituted 1H-imidazo [4,5-b ] pyridin-2 (3H) -ones and uses thereof | 詹森药业有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-11935803-B2 | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-03-19 | — | — | US | disclosed |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-5620978-A | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0743855-A1 | 8-AZA, 6-AZA AND 6,8-DIAZA-1,4-DIHYDROQUINOXALINE-2,3-DIONES AND THE USE THEREOF AS ANTAGONISTS FOR THE GLYCINE/NMDA RECEPTOR | ACEA PHARMACEUTICALS, INC. (US) | 1996-11-27 | — | — | EP | disclosed |
| CN-1118781-A | Heterocyclic compound with activity against diabetes and preparation and application of same | MITSUTAKA CO LTD (JP) | 1996-03-20 | — | — | CN | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |
| WO-1995018616-A2 | 8-AZA, 6-AZA AND 6,8-DIAZA-1,4-DIHYDROQUINOXALINE-2,3-DIONES AND THE USE THEREOF AS ANTAGONISTS FOR THE GLYCINE/NMDA RECEPTOR | ACEA PHARM INC (US) | 1995-07-13 | — | — | WO | disclosed |
| US-4087432-A | HERBICIDES | ELI LILLY AND COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
| US-3963734-A | HERBICIDES, HERBICIDE INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1976-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111405-A1 | O-pyridinequinone derivatives, the composition containing the derivatives, the process for preparation of the derivatives and the use of the derivatives | PTGS2, PTGES2, PTGES | KMT2A 2390/4885HTT 3770/4885ALDH1A1 483/4885 |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | KMT2A 3870/4885HTT 652/4885ALDH1A1 543/4885 |
| US-12145925-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | PARP2, PARP12, PARP1 | KMT2A 440/4885HTT 1662/4885ALDH1A1 1089/4885 |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | KMT2A 1534/4885HTT 507/4885ALDH1A1 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.